Disrupting tumor energy metabolism has emerged as an attractive anticancer strategy, including for non‑small cell lung cancer (NSCLC). Tumor cells rely on multiple, interconnected pathways—such as glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation—and can adaptively rewire metabolism to survive single‑pathway interventions. This metabolic flexibility likely explains why approaches that target only one process have produced suboptimal anticancer effects.
The investigators tested whether combining two metabolic inhibitors, lonidamine and devimistat, could more effectively suppress NSCLC by simultaneously interfering with the major components of cellular energy metabolism. The experimental system centered on the A549 NSCLC cell line and a corresponding xenograft mouse model to assess both in vitro and in vivo antitumor effects.
The study evaluated the combination across a range of cellular and animal endpoints. Assays included measurements of cytotoxicity, colony formation, and determination of optimal combination doses. Mitochondrial function was assessed alongside cellular energy metrics such as adenosine triphosphate (ATP) production and reactive oxygen species (ROS) generation. Apoptosis was measured to determine downstream cell‑death responses. In the animal model, pharmacodynamic analyses were performed to relate drug exposure to biological effects. Additionally, levels of characteristic metabolites were quantified to clarify how the combination altered energy metabolic pathways.
Across the reported experiments, the combination of lonidamine and devimistat produced a synergistic inhibition of tumor growth both in vitro and in vivo. The abstract states that the combined treatment achieved greater antitumor potency than either agent alone when evaluated for cytotoxicity, colony formation, and tumor growth in the xenograft model. Specific numerical values, statistical metrics, and dose schedules are not provided in the abstract and would require the full text for precise details.
Mechanistic readouts linked the observed antitumor synergy to multifaceted disruption of cellular metabolism. Combination therapy was reported to induce ROS production and reduce ATP generation, indicating energetic stress. Mitochondrial morphology and function were impaired under combined treatment, and these mitochondrial effects were associated with activation of apoptosis in tumor cells. Measurement of characteristic metabolites supported that glycolysis, the TCA cycle, and oxidative phosphorylation were collectively affected by the two‑drug regimen, consistent with a broad metabolic blockade rather than a single‑pathway inhibition.
In xenograft experiments, pharmacodynamic analysis was incorporated to connect the combination treatment to biological effects in tumor tissue. The abstract reports synergistic tumor growth inhibition in the animal model, together with metabolic and apoptotic changes consistent with the in vitro findings. Detailed pharmacokinetic parameters, dosing regimens, toxicity assessments, and time course data are not reported in the abstract and would need to be consulted in the main article.
The findings presented provide preclinical evidence that simultaneous targeting of multiple energy metabolic pathways with lonidamine and devimistat can augment antitumor efficacy in NSCLC models. By impairing glycolysis, the TCA cycle, and oxidative phosphorylation, the combination induced energetic collapse (reduced ATP), elevated ROS, mitochondrial dysfunction, and apoptosis—mechanisms that together underlie the reported synergistic effects.
The abstract emphasizes the broader implication that metabolic therapies, when designed to affect multiple interconnected pathways, have potential utility in lung cancer treatment. However, the abstract does not report specific dosing strategies, quantitative efficacy or safety data, nor detailed methodological parameters; these details are necessary to assess translational relevance and would be found only in the full text. Further work, including detailed toxicity evaluation and studies across diverse NSCLC models, would be required before clinical application.